Artwork

内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Orthocell records revenues and targets global expansion in 2025

6:21
 
分享
 

Manage episode 462855985 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO Paul Anderson talked with Proactive’s Tylah Tully about the company’s key achievements in 2024 and its ambitious plans for 2025. Anderson highlighted the success of Remplir, their innovative nerve repair product, which launched in Australia to strong distributor uptake and achieved reimbursement. This success drove record revenues for three consecutive quarters and bolstered Orthocell’s share price and market capitalisation. Anderson explained how Remplir revolutionises nerve repair by minimising sutures, reducing surgical damage, and improving patient recovery times. Orthocell is advancing global expansion plans, with regulatory submissions in the US, Canada, Thailand, Europe, and Brazil. “This product is addressing a strong unmet clinical need,” Anderson stated, emphasising the company’s goal of capturing a 20% share of the $3.2 billion global nerve repair market. In 2025, Orthocell aims to strengthen its US infrastructure, collaborate with leading surgeons, and scale Remplir’s commercialisation worldwide. #ProactiveInvestors #Orthocell #Remplir #NerveRepair #ASXOCC #HealthcareInnovation #MedicalDevices #FDAApproval #GlobalExpansion #ProactiveStudio #2025Growth
  continue reading

605集单集

Artwork
icon分享
 
Manage episode 462855985 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO Paul Anderson talked with Proactive’s Tylah Tully about the company’s key achievements in 2024 and its ambitious plans for 2025. Anderson highlighted the success of Remplir, their innovative nerve repair product, which launched in Australia to strong distributor uptake and achieved reimbursement. This success drove record revenues for three consecutive quarters and bolstered Orthocell’s share price and market capitalisation. Anderson explained how Remplir revolutionises nerve repair by minimising sutures, reducing surgical damage, and improving patient recovery times. Orthocell is advancing global expansion plans, with regulatory submissions in the US, Canada, Thailand, Europe, and Brazil. “This product is addressing a strong unmet clinical need,” Anderson stated, emphasising the company’s goal of capturing a 20% share of the $3.2 billion global nerve repair market. In 2025, Orthocell aims to strengthen its US infrastructure, collaborate with leading surgeons, and scale Remplir’s commercialisation worldwide. #ProactiveInvestors #Orthocell #Remplir #NerveRepair #ASXOCC #HealthcareInnovation #MedicalDevices #FDAApproval #GlobalExpansion #ProactiveStudio #2025Growth
  continue reading

605集单集

Semua episod

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南

边探索边听这个节目
播放